



About Roche

Australian Pharmaceutical Business

Roche Products Pty Limited, the Australian pharmaceutical division of the international Roche Group, has been committed to improving the health and wellbeing of people in Australia for over 60 years.

Roche first distributed its products from premises in central Sydney before moving to the Dee Why/Cromer area of Sydney's Northern Beaches where it had its headquarters and manufacturing facilities for several decades. Recently, the company relocated its headquarters to the Sydney CBD, on the edge of the city's newest waterfront precinct of Barangaroo.

Today, the company is dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Over the last two decades, Roche has become a leading specialist in biotechnology focused on developing medicines in oncology (cancer), immunology, ophthalmology, infectious diseases and neuroscience.

Roche invests around 10 billion US Dollars each year in research and development worldwide, including approximately 37 million Australian Dollars in pharmaceutical research and development in Australia.

Roche has an industry-leading pharmaceutical pipeline with 74 new molecular entities (NMEs) in clinical development.

Australian patients have access to around 40 Roche medicines, and the company is the leading provider of cancer medicines in Australia by sales.

Roche has over 350 employees working in 5 states across Australia.

Roche has been the leading healthcare company in the Dow Jones Sustainability Indices since 2009.

Further information about Roche is available on our local website: roche-australia.com or via Roche Corporate Affairs: australia.corporate_affairs@roche.com.

October 2017

Material number: 37561848

Roche Products Pty Limited, 30-34 Hickson Road, Sydney NSW 2000. ABN 70 000 132 865

Pharmaceuticals Division, www.roche-australia.com 02 9454 9000